secwatch.observer — SEC 8-K summary
======================================

Issuer:     Emmaus Life Sciences, Inc. (EMMA)
CIK:        0000822370
Form:       8-K
Filed at:   2022-03-31T23:59:59+00:00
Accession:  0001213900-22-016970
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Emmaus Life Sciences FY2021 revenue $20.6M; net loss $15.9M vs prior-year net income
--------------------------------------------------------------------------------

- Net revenue $20.6M, down 11% from $23.2M in 2020; sales volume steady but discounts hurt.
- Operating loss $6.1M vs $32,000 loss in 2020; R&D and selling expenses increased.
- Net loss attributable to common $15.9M ($0.32 per share) vs net income $1.4M ($0.03) in 2020.
- Cash $2.3M at Dec 31, 2021; Endari added to Florida Medicaid preferred drug list, UAE approval obtained.
- Licensed IRAK4 inhibitor from Kainos for cancer; telehealth partnership with UpScript launched.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/822370/000121390022016970/0001213900-22-016970-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/822370/000121390022016970/ea157399-8k_emmauslife.htm
  HTML page:      https://secwatch.observer/filing/0001213900-22-016970

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer